Viracta Therapeutics Correlations

VIRXDelisted Stock  USD 0.03  0  7.38%   
The correlation of Viracta Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.

Viracta Therapeutics Correlation With Market

Good diversification

The correlation between Viracta Therapeutics and DJI is -0.14 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Viracta Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
  
The ability to find closely correlated positions to Viracta Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Viracta Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Viracta Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Viracta Therapeutics to buy it.

Moving against Viracta Pink Sheet

  0.58MLYS Mineralys Therapeutics,PairCorr
  0.32DRMA Dermata TherapeuticsPairCorr

Related Correlations Analysis

Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Correlation Matchups

Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.
High positive correlations   
ALXORLYB
RLYBVINC
TARARLYB
ALXOVINC
TARAVINC
TNYARLYB
  
High negative correlations   
ALXOTRVI
CABATRVI
TRVIRLYB
TRVITNYA
TRVIVINC
TRVILYRA

Risk-Adjusted Indicators

There is a big difference between Viracta Pink Sheet performing well and Viracta Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Viracta Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
VINC  6.79 (2.14) 0.00  1.24  0.00 
 13.02 
 97.80 
TCON  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
RLYB  3.13 (0.63) 0.00 (1.74) 0.00 
 6.32 
 18.17 
TNYA  5.95 (1.09) 0.00 (0.33) 0.00 
 11.67 
 80.00 
LYRA  2.89  0.10  0.02  0.29  3.32 
 5.88 
 25.31 
TRVI  3.67  0.73  0.25 (0.59) 3.01 
 7.11 
 44.27 
SQZ  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
TARA  3.74 (0.19) 0.00 (0.19) 0.00 
 9.33 
 19.11 
ALXO  5.79 (0.79) 0.00  2.90  0.00 
 15.43 
 45.05 
CABA  4.31 (0.49) 0.00 (0.43) 0.00 
 8.87 
 26.78 

View Viracta Therapeutics Related Equities

 Risk & Return  Correlation

Viracta Therapeutics Corporate Management

Still Interested in Viracta Therapeutics?

Investing in delisted pink sheets can be risky, as the pink sheet is no longer traded on a public exchange and can therefore be difficult to sell. Delisting typically occurs when a company has failed to meet exchange requirements or has been acquired. Before investing, it's important to thoroughly research the company, including its financial health and prospects for the future, as well as the reasons for its delisting. Additionally, it may be difficult to find accurate and up-to-date information on the company and its stock.